Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > $TLTFF .076 TO .255 Great developments and chart!!

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Mar 01, 2021 8:21am

302 Views

Post# 32683838

RE:$TLTFF .076 TO .255 Great developments and chart!!

It's important to understand that Theralse is exucting a PIVOTAL STUDY... NO PHASE THREE REQURIED.

The PivotalPhase 2 NMIBC trial with 15 treated and 20 to 25 patients needed to be considered for Breakthrough Therapy Designation is solidly on track.

The company is having great success!

More treatments will be coming soon with 10 hospitals cleared and ready to treat patients.

Further, this is a Pivotal Phase II Non-Muscle Invasive Bladder Cancer study. A Phase 3 study will not be required.

----------------------------

Toronto, Ontario – February 24, 2021,Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (“UWH”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“).

floatinketucky wrote: Some great consolidaton as the stock moves back to the high side of our 5 year range (.435 USD). This stock will be breaking that topside 5 year range.

It's moving up because the company is having great success and CV19 had it way way way undervalued and delayed.

Many new hospitals recently added
10 hospitals approved and ready to treat patients now!

15 patients treated with current new patients treated!

Other PRs pending in the near term.

The scale up of treatments is going great.

TLTFF.. BACK ON TRACK AND A SOLID SOLID VALUE!